Search details
1.
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
Nature
; 475(7355): 222-5, 2011 Jun 08.
Article
in English
| MEDLINE | ID: mdl-21654748
2.
Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Prostate
; 76(9): 810-22, 2016 06.
Article
in English
| MEDLINE | ID: mdl-26990456
3.
Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.
Mol Ther
; 22(1): 18-27, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24048441
4.
Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.
Int J Mol Sci
; 14(5): 10483-96, 2013 May 21.
Article
in English
| MEDLINE | ID: mdl-23698775
5.
Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
Mol Cancer Ther
; 21(7): 1115-1124, 2022 07 05.
Article
in English
| MEDLINE | ID: mdl-35499386
6.
Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.
Am J Respir Cell Mol Biol
; 44(2): 230-7, 2011 Feb.
Article
in English
| MEDLINE | ID: mdl-20395632
7.
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
J Neurooncol
; 104(1): 83-92, 2011 Aug.
Article
in English
| MEDLINE | ID: mdl-21116835
8.
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
J Clin Invest
; 130(3): 1405-1416, 2020 03 02.
Article
in English
| MEDLINE | ID: mdl-32015231
9.
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model.
J Cell Biochem
; 107(1): 58-64, 2009 May 01.
Article
in English
| MEDLINE | ID: mdl-19259948
10.
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.
Cancer Res
; 67(19): 9417-24, 2007 Oct 01.
Article
in English
| MEDLINE | ID: mdl-17909051
11.
Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway.
Mol Cancer Res
; 4(6): 371-7, 2006 Jun.
Article
in English
| MEDLINE | ID: mdl-16778084
12.
Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies.
Hum Antibodies
; 16(3-4): 117-25, 2007.
Article
in English
| MEDLINE | ID: mdl-18334747
13.
Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment.
Oncotarget
; 8(65): 109151-109160, 2017 Dec 12.
Article
in English
| MEDLINE | ID: mdl-29312597
14.
Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
Oncotarget
; 8(24): 39117-39130, 2017 Jun 13.
Article
in English
| MEDLINE | ID: mdl-28388572
15.
Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
Mol Cancer Ther
; 16(2): 312-322, 2017 02.
Article
in English
| MEDLINE | ID: mdl-27980102
16.
Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.
Cancer Cell
; 32(5): 654-668.e5, 2017 11 13.
Article
in English
| MEDLINE | ID: mdl-29136508
17.
Mutant KRAS promotes malignant pleural effusion formation.
Nat Commun
; 8: 15205, 2017 05 16.
Article
in English
| MEDLINE | ID: mdl-28508873
18.
Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.
PLoS One
; 10(6): e0130565, 2015.
Article
in English
| MEDLINE | ID: mdl-26090669
19.
Mast cells mediate malignant pleural effusion formation.
J Clin Invest
; 125(6): 2317-34, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25915587
20.
Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Mol Oncol
; 8(7): 1231-9, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-24816187